baber/WOPTO huggingface dataset:
Patent NZ-218648-A (NZ)
Title: Thiadiazoles and antiviral compositions
Inventor: RIEDER B J
IPC: A01N43/82
Filed: 1986-12-16
Abstract: (1) 1,3,4-Thiadiazole-2-cyanamide and derivs. of formula (I) and their salts are new. In (I), R1 = H; R2 = CN; or R1+R2 = =C(SR6)NH2 or =C(NH2)2; R6 = 1-4C alkyl, cyano-(1-4C)alkyl or pyridyl-(1-4C)alkyl. (2) In vitro antiviral method for protecting mammalian cells in culture comprises adding to the culture a cpd. (I) in which either (A) R1 = H; R2 = CN or =CH-NHR3; or R1+R2 = =C(NH2)2 or =CR5-NHR3(1); R3 = COOR4; R3(1) = H or COOR4; R4 = 1-10C alkyl, 2-10C alkenyl or Ph, each opt. substd.; R5 = H or SR6; R6 = 1-4C alkyl, cyano-(1-4C)alkyl or pyridyl-(1-4C)alkyl; or (B) as defined for (A) except that R1+R2 = =CR5NHR31 only; and R3, R31 = H or COOR4.
Patent NZ-225596-A (NZ)
Title: Dna constructs containing kluyveromyces #a#-factor leader sequence for directing the secretion of heterologous peptides
Inventor: VAN DEN BERG JOHANNES A
IPC: C12N15/59
Filed: 1988-07-28
Abstract: DNA constructs that are useful for providing secretory expression of heterologous polypeptides in yeast comprising a DNA sequence that includes a Kluyveromyces  alpha -factor leader sequence linked to the heterologous polypeptide by a yeast processing signal. Constructs employing the K. lactis  alpha -factor leader and processing signal sequences, with and without spacer, linked to prochymosin are exemplified.
Patent NZ-226904-A (NZ)
Title: Hiv-2 env protein polypeptides and their preparation and use
Inventor: BANNWARTH WILHELM
IPC: A61K39/21
Filed: 1988-11-09
Abstract: Polypeptides which include at least one antigenic and/or immunogenic determinant group of the envelope protein (env) of the HIV-2 virus, and the preparation thereof by recombinant DNA technology, and the DNA sequences, expression vectors and transformed single-cell organisms used in this process are described. Also described are processes for detecting HIV antibodies or HIV viruses in human sera or other biological fluids. <IMAGE>
Patent NZ-228313-A (NZ)
Title: Asp 149 -human growth hormone
Inventor: BECKER GERALD WAYNE
IPC: C12N15/00
Filed: 1989-03-13
Abstract: A desamido derivative of human growth hormone has been produced and characterized. The derivative arises from a selective desamidation of Asn<1><4><9>. The resulting Asp<1><4><9>-hGH exhibits full biological activity.
Patent NZ-232195-A (NZ)
Title: Phenyl-, pyridyl- and thienyl-substituted carboxamide and sulphonamide derivatives and pharmaceutical compositions
Inventor: ALIG LEO
IPC: C07C311/13
Filed: 1990-01-23
Abstract: The novel carboxylic acid and sulphonic acid amides of the formula
 R<1>-A-(W)a-X-(CH2)b-(Y)c-B-Z-COOR     (I) in which R<1>, A, W, X, Y, B, Z, R, a, b and c have the meaning given in the description, can be used in the treatment of thromboses, apoplexy, cardiac infarcts, inflammations, arteriosclerosis and tumours. They are prepared by removal of the protective groups in corresponding compounds having protected amidino or guanidino groups.
Patent NZ-239475-A (NZ)
Title: Thiadiazole and oxadiazole derivatives, preparation and pharmaceutical compositions thereof
Inventor: SAUERBERG PER
IPC: A61P27/02
Filed: 1991-08-20
Abstract: The present invention relates to therapeutically active azacyclic compounds, a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful as stimulants of the cognitive function of the forebrain and hippocampus of mammals and especially in the treatment of Alzheimer's disease, severe painful conditions and glaucoma.
Patent NZ-240241-A (NZ)
Title: Process for hydrolysis of resin in pulp comprising enzymatic hydrolysis simultaneously with reductive bleaching of the pulp
Inventor: PEDERSEN LARS SAABY
IPC: D21C9/10
Filed: 1991-10-15
Abstract: PCT No. PCT/DK91/00315 Sec. 371 Date Mar. 3, 1993 Sec. 102(e) Date Mar. 3, 1993 PCT Filed Oct. 17, 1991 PCT Pub. No. WO92/07138 PCT Pub. Date Apr. 30, 1992.Resin can be hydrolyzed enzymatically during the reductive bleaching (e.g. with sodium dithionite) commonly used in pulp manufacture. The enzyme treatment necessitates little or no change of commonly used bleaching conditions.
Patent NZ-240426-A (NZ)
Title: Fungicidal composition comprising a triazolyl derivative and either
Inventor: KUNG RUTH
IPC: A01N43/40
Filed: 1991-10-31
Abstract: Fungicidal compsn. contains:(a) cyproconazole of formula (I) or salt or metal complex; (b) fenpropidin of formula (II) or salt; and (c) carrier material. (I) is known from DE3406993 and (II) is known from DE2752135.
Patent NZ-251047-A (NZ)
Title: Acylaminoindole derivatives and medicaments
Inventor: MACOR JOHN E
IPC: A61P3/04
Filed: 1993-03-04
Abstract: PCT No. PCT/US93/01807 Sec. 371 Date Sep. 14, 1994 Sec. 102(e) Date Sep. 14, 1994 PCT Filed Mar. 4, 1993 PCT Pub. No. WO93/21180 PCT Pub. Date Oct. 25, 1993.    <IMAGE>  (I)  Compounds of formula (I) where n is 0, 1, or 2; m is 0 or 1; Y and W are each an amino acid residue; R1 is hydrogen, C1-C6 alkyl, C3-C6 alkenyl, C3-C6 alkynyl, aryl, C1-C3 alkylaryl, or C1-C3 alkylheteroaryl, and -(CH2)pR3; R2 is CF3, C1-C6 alkyl, aryl, C1-C3 alkylaryl, and -OR5; R3 is cyano, trifluoromethyl, or -OR4; R4 is hydrogen, C1-C6 alkyl, C1-C3 alkylaryl, or aryl; R5 is C1-C6 alkyl, C1-C3 alkylaryl, or aryl; R6 is hydrogen, -OR7, or -NHCOR7; R7 is hydrogen, C1 to C6 alkyl, aryl or C1 to C3 alkyl-aryl; p is 1, 2, or 3; and the above aryl groups and the aryl moieties of the above alkyl-aryl groups are independently selected from phenyl and substituted phenyl, wherein said substituted phenyl may be substituted with one to three groups selected from C1 to C4 alkyl, halogen, hydroxy, cyano, carboxamide, nitro, and C1 to C4 alkoxy and the pharmaceutically acceptable salts thereof. These compounds are useful in treating migraine and other disorders. These compound are useful psychotherapeutics and are potent serotonin (5-HT1) agonists and may be used in the treatment of depression, anxiety, eating disorders, obesity, drug abuse, cluster headache, migraine, pain, and chronic paroxysmal hemicrania and headache associated with vascular disorders, and other disorders arising from deficient serotonergic neurotransmission. The compounds can also be used as centrally acting antihypertensives and vasodilators.
Patent NZ-253339-A (NZ)
Title: Yeast product; method of production from lactose containing substrate; substrate is filtered, inoculated with a yeast strain and fermented in a bioreactor
Inventor: DE BOER RUDOLF
IPC: A23L1/30
Filed: 1993-05-27
Abstract: A modified cultured yeast product for human and animal consumption is produced by combining yeast cream and yeast centrate to produce a cream/centrate mixture, autolyzing the mixture, inactivating by heating the mixture and optionally drying. After autolysis, hydrolysis may be carried out by the use of acids, alkalis or enzymes. The yeast cream and yeast centrate are preferably produced by culturing Kluveromyces marxianus or Candida intermedia in a whey permeate and separating yeast cream and yeast centrate from the cultured whey permeate. The cream and centrate are combined such that the ratio of total solids of cream to total solids of centrate is between about 0.3 and 1.6 and preferably about 1:1.
Patent NZ-264991-A (NZ)
Title: 5-(4-hydroxyphenyl)-1,3,4-oxadiazol-2(3h)-one derivatives and pharmaceutical compositions
Inventor: KOENIG JEAN-JACQUES
IPC: A61P25/00
Filed: 1994-11-25
Abstract: The invention relates to 1,3,4-oxadiazol-2(3H)-one derivatives, of general formula (I) <IMAGE>  in which   R1 represents either a hydrogen atom or a linear or branched (C1-4)alkyl group, which is substituted by a hydroxyl, phenoxy, (C1-4)alkoxy, (C1-4)alkylthio, mercapto, (C1-4)alkoxy(C1-4)alkoxy, di(C1-4)alkylamino or N-(C1-4)alkyl-N-propynylamino group, or a (C3-4)alkynyl group, and R2 represents either a linear or branched (C1-8)alkyl group, which is substituted by one or a number of halogen atoms and/or a hydroxyl, 1-imidazolyl or 3-tetrahydropyranyl group, or a trifluoro(C3-5)alkenyl group, in the form of pure enantiomers or of mixtures of enantiomers, including racemic mixtures, and their addition salts with pharmaceutically acceptable acids. Application of them as monoamine oxidase, in particular MAO-B, inhibitors.
Patent NZ-272904-A (NZ)
Title: Camptothecin-21-carboxamide derivatives; anti-tumour pharmaceuticals
Inventor: YAEGASHI TAKASHI
IPC: A61P35/00
Filed: 1995-08-31
Abstract: New camptothecin derivatives of the general formula (1), preparations thereof and antitumor agents comprising the same, <CHEM> wherein R<1> represents a hydrogen atom or a C1-C6 alkyl group, R<2> represents a hydrogen or a C1-C6 alkoxy group, R<3> represents a hydrogen or halogen atom or a C1-C6 alkyl, C1-C6 alkoxy, hydroxyl, C2-C6 acyloxy or methoxyethoxymethoxy group, R<4> represents a hydrogen or halogen atom, and R<5> represents a C1-C6 alkyl, C3-C6 unsaturated alkyl, alkylthioalkyl, alkoxyalkyl, pyridyl or substituted phenyl group, with the proviso that all of the R<2>, R<3> and R<4> substituents should not be a hydrogen atom.
Patent NZ-280833-A (NZ)
Title: Fuel dispenser incorporates separate bus connected function control nodes
Inventor: ATCHLEY HANS B
IPC: B67D7/22
Filed: 1996-01-16
Abstract: A fuel dispenser comprises a distributed dispenser control including a plurality of microcontroller nodes and a communications bus connecting the microcontroller nodes each of which is associated with a respective component or group of components. This reduces the amount of information that requires to be processed by a single processing unit enabling additional features to be more easily incorporated in a basic dispenser design, or to be retrofitted to dispensers employing the present invention. <IMAGE>
Patent NZ-298699-A (NZ)
Title: 3-amino-1,2-dihydropyrid-1-yl(and 5-amino-1,6-dihydro-6-oxo(and 5,6-dioxo)pyrimidin-1-yl)-acetyl-argininal derivatives, useful for the treatment of blood coagulation and thrombosis
Inventor: TAMURA SUSAN YOSHIKO
IPC: C07D239/545
Filed: 1995-12-13
Abstract: The compound of formula (I), wherein: X is -S(O)2-, -N(R')-S(O)2-, -(C=O)-, -OC(=O)-, -NH-C(=O)-, -P(O)(R")- and a direct link, wherein R' is H, alkyl, aryl or aralkyl, and R" is NR', OR', R', or SR', with the proviso that R" is not NH, OH, H, or SH, and; R1 is: alkyl, alkyl substituted with optionally substituted cyclic alkyl, or is optionally substituted 4-10 membered heterocycloalkyl, 4-10 membered heterocyclo, alkenyl, aryl, cyclic alkyl, heteroaryl, aralkyl, heteroaralkyl, aralkenyl or heteroaralkenyl, or a group of formula 13-16, or is difluoromethyl, perfluoroalkyl, perfluoroaryl, perfluoroaralkyl or hydrogen provided that if X is not a direct link, then R1 is not H; i is 0, 1 or 2; the heteroatoms are O, N, or S(O)i R2 is H, alkyl or alkenyl R3 is a group of formula II, wherein W is nitrogen or carbon; Het is a group of formula III, wherein R4, R5, R6, and R7 are as defined in the specification. The compounds of formula I are useful in treating thrombosis or for inhibiting blood coagulation.
Patent NZ-309819-A (NZ)
Title: Bouquet presentation device
Inventor: CHARRIN PHILIPPE
IPC: B65D85/50
Filed: 1996-05-23
Abstract: The holder consists of a cone made from a folded semi-circle of material, with a tab (3) and slits (4) to adjust its size, and opening vanes (11) at the top to make a hole through which the stems of a bouquet of flowers can be inserted. The holder can be held in shape with a ribbon threaded through holes (6) near its upper end, and a sheet (8) of wrapping paper can be used to cover the base and sides of the cone for presentation.  Variants of the design, either conical in cylindrical in shape, can be made with a base to hold a small amount of water which keeps the flowers fresh, e.g. as a temporary vase, or for transport.
Patent NZ-336225-A (NZ)
Title: Preparation in form of a matrix material-auxiliary agent compound containing optionally an active substance
Inventor: MULLER RAINER H
IPC: A61K9/16
Filed: 1997-12-10
Abstract: A preparation in the form of a compound containing a matrix material, with an auxiliary substance phase with at least one auxiliary substance and/or an active substance phase with at least one active substance, and a matrix material phase with at least one polymer and/or lipid. The preparation is characterized in that the matrix material phase is incoherent, and the auxiliary and/or active substance phase of the preparation is coherent. The preparation is suited for the production of larger matrix units with controlled release characteristics in accordance with known methods, and in particular for the production of tablets by means of direct compressing.
Patent NZ-338006-A (NZ)
Title: Aminopyrimidine derivatives, their preparation, and pharmaceutical compositions thereof; useful for inhibiting nitric oxide synthase activity
Inventor: MCINALLY THOMAS
IPC: A61P11/06
Filed: 1998-04-07
Abstract: A compound of formula (I) and a process for preparing this compound, wherein: R1 is H, alkyl, alkoxy, halogen or trifluoromethyl; R2 represents H or alkyl; A represent a five membered heterocyclic aromatic ring containing 1-3 heteroatoms which may be the same or different and which are selected from O, N and S; or A is a six membered heterocyclic aromatic ring containing 1-3 N atoms; i) R3 represents phenyl, or a six membered heterocyclic aromatic ring containing 1-3 N atoms, or a five-membered heterocyclic aromatic ring containing 1 to 3 heteroatoms which may be the same or different and are selected from O, N and S, which phenyl or heterocyclic aromatic ring may be optionally substituted; and R4 represents H or alkyl; or ii) R3 represents alkyl, alkenyl, or alkynyl and R4 represents H or alkyl; or iii) R3 and R4 together represent (CH2)a -Z-(CH2)b, where Z represents N(COOR7), or iv) R3 and R4 together represent (CH2)a -Z-(CH2)b, where Z represents N(COR8); a and b are 1-3 (provided that a + b is 3 or 4); R7 and R8 are as defined in the specification; or a pharmaceutically acceptable salt, enantiomer, racemate or tautomer thereof. The compounds of formula (I) can be used to prepare pharmaceutical compositions, and are useful for the treatment or prophylaxis of human diseases or conditions in which the inhibition of nitric oxide synthase activity is beneficial.
Patent NZ-501274-A (NZ)
Title: Degradable polymer fibres comprising polylactide and material made from the fibres
Inventor: BUEHLER NANCY UZELAC
IPC: D04H1/54
Filed: 1998-05-04
Abstract: A fibrous polylactide material comprises a plurality of polylactide containing fibres prepared from a polylactide composition containing polylactide having less than 5wt% R-lactic acid, a lactide concentration of less than 0.5wt% and a number average molecular weight of 25,000 and 150,000. The plurality of polylactide containing fibres exhibits a crystallinity of greater than 20 J/g, a tenacity of greater than 1.5 grams/denier and an average fibre boiling water shrinkage propensity of less than 15%. The plurality of polylactide containing fibres is prepared by spunbonding the polylactide composition at a fibre velocity of 1,000 to 3,000m/min, a throughput of 0.5 and 1.2g/min/capillary and a temperature of 220-245oC and is deposited as a web.
Patent NZ-505525-A (NZ)
Title: Polymers imprinted with phenols for the binding of phenols, and a method and sensor for the detection and/or measurement of a phenol by measuring the binding of phenol to the polymer
Inventor: COOK CHRISTIAN
IPC: G01N27/416
Filed: 2000-06-30
Abstract: A  method  for the detection and/or measurement  of  a phenol comprising: i)    Contacting  the  sample to be tested  with  a  polymer imprinted with the phenol or an analogue thereof ii)  Measuring binding of the phenol to the polymer The   phenol  is  phenol  substituted  with  from  1  to   3 substituents selected from C1-C6 alkyl groups. Also described is a sensor for detecting/measuring propofol, comprising a probe having an imprinted polymer as  described above. Also   described  is  an  imprinted  polymer   prepared   by polymerising  a  polymerisable  monomer,  to  which   phenol substituted with from 1 to 3 substituents selected from  C1- C6  alkyl  groups  is  covalently bound  by  a  hydrolysable linker, and subsequently removing the substituted phenol  by hydrolysis. Also described is an imprinted polymer prepared by preparing or  cross-linking  a  polymer in the presence  of  a  phenol substituted with from 1 to 3 substituents selected from  C1- C6  alkyl  groups and subsequently chemically or  physically removing the substituted phenol.
Patent NZ-505821-A (NZ)
Title: Pharmaceutical compositions of uridine triphosphate
Inventor: PENDERGAST WILLIAM
IPC: A61K9/00
Filed: 1998-12-23
Abstract: A sterile pharmaceutical composition comprising uridine 5'-triphosphate (UTP) and sterile aqueous solution with a concentration of UTP between 0.1 mg/ml and 100 mg/ml; an osmolarity value between 250 and 450 mOsM; and a pH level between 6.0 and 8.5. The composition is useful for increasing expectoration.
Patent NZ-507523-A (NZ)
Title: Method for treating ischemia with deltorphin
Inventor: OELTGEN PETER R
IPC: A61K38/08
Filed: 1999-04-30
Abstract: Described is a use of deltorphin in the manufacture of a medicament for treating ischemia in a mammal.  The deltorphin is selected from Deltorphin I, deltorphin II or combinations of deltorphins I and II.  A deltorphin concentration of about 0.5-20 mg/kg, or alternatively 1-1000 ug/kg body weight of the mammal in a physiologically acceptable formulation is administered up to four hours after an ischemic episode.  Deltorphins may also be administered prior to or concurrently with onset of ischemia.  Cerebral or spinal cord ischemia or ischemic heart disease may be treated with the medicament.
Patent NZ-508775-A (NZ)
Title: Enhanced intra vaginal devices for sustained release comprising cyclodextrins
Inventor: BUNT CRAIG ROBERT
IPC: A61F6/08
Filed: 1998-06-05
Abstract: An intra-vaginal device insertable and retainable within the vagina of a target species mammal for a retention period over which an intravaginally effective active agent in a moulded matrix or moulded matrices of the device is released to the mammal, the device being characterised in that the matrix or matrices have been moulded whilst impregnated in addition to the active agent with sufficient cyclodextrin to achieve, within said retention period, a sustained elevation in the plasma serum of the mammal of the active agent or at least one active metabolite thereof.  Used for oestrus synchrony enhancement of an individual mammal or a mammalian herd.
Patent NZ-511715-A (NZ)
Title: A breakfast cereal biscuit, which is at least 20% by weight waxy grain, that has an extended bowl life and crisp texture
Inventor: LEWIS DEBORAH ANN
IPC: A23L7/139
Filed: 1999-11-17
Abstract: A breakfast cereal biscuit (BCB) is provided comprising a waxy grain in an amount of at least 20% by weight of total grain content.  The grain has been hydrated and cooked either sequentially or simultaneously or both, by rolling it into flakes, and either agglomerating the flakes and toasted them into a desired biscuit shape or toasting the flakes and agglomerating them into the desired biscuit shape. A process for the production of the breakfast cereal biscuit is also provided. The BCB typically exhibits extended bowl life, has improved nutritional qualities, is tender and crisp in texture and requires reduced energy in the manufacturing process when compared with standard flaked wheat breakfast cereal biscuits.
Patent NZ-513095-A (NZ)
Title: Gaming machine with bonus games where player selects display symbols and their functions within the available indicia
Inventor: BENNETT NICHOLAS LUKE
IPC: G07F17/32
Filed: 2001-07-23
Abstract: The machine is arranged so that if a predefined event occurs during the playing of the underlying game, a feature game series will be triggered to begin. Prior to the commencement of the feature game series, the player is given the option to select, from a set of indicia, at least one indicia to have at least one of the particular functions to that feature game. For example, the player may choose a particular symbol as a bonus symbol. The invention also provides for the player's selection choices to affect the volatility of the game in that a particular selection may make a win less likely but more rewarding.
Patent NZ-515052-A (NZ)
Title: Method of producing a method product using a hammer mill
Inventor: HOWSAM STUART
IPC: A23L13/40
Filed: 2000-05-18
Abstract: A  method  of manufacturing a texturised proteinaceous meat  analogue  product, including  subjecting,  in  a  food extruder, a mixture containing: (a)    About  40  to  95%  by  weight  edible  proteinaceous materials   selected   from   the   group   consisting    of predetermined mixtures of defatted soy flour, soy meal,  soy concentrate,  cereal  gluten in vital  or  starch-containing form and egg white; and (b)   Up to about 7% by weight of edible mineral binding and cross-linking  compounds; to mechanical pressure  and  added heat  sufficient to convert the mixture into a hot,  viscous protein lava; (c)    Extruding  the  protein  lava  through  and  from   a temperature  controlled cooling die which cools and  reduces the  viscosity  of  the protein lava to obtain  a  cohesive, texturised,  extrudate  slab  or  ribbon  in  which  vapour- flashing is substantially inhibited; and (d)   Subjecting the solidified extrudate slab or ribbon  to mechanical  shredding in a hammer mill having a  cage  plate with   a  plurality  of  elongate  discharge  openings   and plurality  of  hammer  bars hinged to discs  attached  to  a rotating  shaft,  so as to obtain a plurality  of  extrudate shreds  that resemble in consistency and texture  flaked  or shredded meat.   S(11) 515079   (22) 16 Mar 2000 (54)  A method for making positive grids and lead-acid cells and batteries using such grids (86) PCT/US00/07146 (87) WO00/60677 (51) IPC7:H01M4/14,72,68 (71) EXIDE TECHNOLOGIES (72) Rao, Purushothama; (31) 99 285624 (32) 3 Apr 1999     (33) US (74)  A  J PARK, 6th Floor, Huddart Parker Building, 1  Post Office Square, Wellington, New Zealand (57)  A  method  for  making positive  grids  for  lead-acid batteries   from   calcium-tin-silver   lead-based    alloys comprises casting an alloy strip and then rolling the  strip at  a  temperature between about the solvus temperature  and the  peritectic  temperature of  the  alloy,  quenching  the rolled  strip, then, preferably, heat aging at a temperature of  200  F.  to  500 F., and fabricating into  the  positive grid,  such  grids  having  enhanced  mechanical  and   high temperature corrosion resistance characteristics
Patent NZ-515238-A (NZ)
Title: Inhibitors of LFA-1 binding to ICAMs and uses thereof
Inventor: FOWLER KERRY
IPC: C07D215/36
Filed: 2000-04-03
Abstract: Disclosed are pharmaceutical compositions comprising substituted diaryl sulfide compounds of formula (I), that bind to the I domain of LFA-1 in preference to an ICAM, wherein: A and B are aryl groups selected from 5-and 6-membered aromatic rings, R1, R2 and R3, are independently H, -Ra wherein Ra is H or alkyl, -O-Ra, -halo, -NRbRc wherein Rb and Rc are independently H, alkyl, -CH2-aryl, -NO2, -C(=O)Ra, -perfluoroRa, -N-C(=O)Ra, -(CH2)n-NRbRc wherein n is from 1-6, or a 5- or 6-membered heterocyclic ring, R4, R5 and R6, are independently H, -Ra, -O-Ra, -halo, -NRbRc, -NO2, -C(=O)Ra, -perfluoroRa, -N-C(=O)Ra, -(CH2)n-NRbRc or a 5- or 6-membered heterocyclic ring. The compounds of formula (I) are also used in the manufacture of medicaments for the treatment of inflammatory diseases.